Biotechnology Industry Veteran Richard Brewer Joins SRI International Board of Directors | SRI International

Toggle Menu

Biotechnology Industry Veteran Richard Brewer Joins SRI International Board of Directors

MENLO PARK, California - January 9, 2006 — SRI International, an independent nonprofit research and development organization, today announced that Richard B. Brewer was recently elected to its board of directors , whose prestigious members represent the business , financial, academic and government sectors. Mr. Brewer's expertise in the biotechnology industry complements the board's areas of industry expertise as they counsel SRI on bringing its world-leading research and technologies to the marketplace. With his election, Brewer becomes the eighth member of the SRI board.

Recognized as a biotech pioneer, Mr. Brewer, 53, has nearly 30 years of experience overseeing operations at several notable biopharmaceutical and medical device companies. He is currently Managing Partner of Crest Asset Management, providing guidance to and investing in promising biotechnology opportunities. Previously , Mr. Brewer was CEO and President of Scios Inc. , where he led the company in achieving FDA approval for Natrecor® (Nesiritide), the first new drug for congestive heart failure in more than a decade, and guided Scios through its $2.4 billion merger with Johnson & Johnson.

"Dick brings tremendous biopharmaceutical industry expertise to the SRI board," said Samuel Armacost, Chairman of the Board at SRI International. "His perspective will be particularly useful to SRI as we aggressively grow our biosciences business. His decades of experience will be of significant help in defining and implementing SRI's growth strategies, licensing arrangements and partnerships."

Mr. Brewer also served as COO of Heartport, a cardiovascular device company developing minimally invasive approaches to major heart surgery. Before Heartport, he was with biotech leader Genentech for over a decade, ultimately serving as senior vice president of sales and marketing and senior vice president of Genentech Europe and Canada. As head of global product launches, he was responsible for growing the franchise for Activase®, Genentech's blockbuster heart attack drug.  

Mr. Brewer is on the boards of Arginox, Corgentech, Dendreon, Agensys and Corus Pharma. He is a past chairperson of the American Heart Association's Pharmaceutical Roundtable. He is also an advisory board member at the Kellogg Graduate School of Management and the Center for Biotechnology at Northwestern University.  

Mr. Brewer holds an M.B.A. from Northwestern University and a B.S. from Virginia Polytechnic Institute & State University.

About SRI International
Silicon Valley-based SRI International ( is one of the world's leading independent research and technology development organizations. Founded as Stanford Research Institute in 1946, SRI has been meeting the strategic needs of clients for 60 years. The nonprofit research institute performs client-sponsored research and development for government agencies, commercial businesses and private foundations. In addition to conducting contract R&D, SRI licenses its technologies, forms strategic partnerships and creates spin-off companies.


# # #